University of Virginia School of Medicine
Charlottesville, Virginia
Dr. Linda Duska MD MPH is a Professor of Obstetrics and Gynecology, Division of Gynecologic Oncology at the University of Virginia Shool of Medicine in Charlottesville. She provides clinical care for women with gynecologic cancer includig surgery and chemotherapy, as well as for women with complex gynecologic surgical problems. Dr. Duska has been in practice since 1998, when she completed her Gynecologic Oncology Fellowship at the Massachusetts General Hospital in Boston, and moved to UVA in 2008 to assume the role of Gynecologic Oncology Fellowship Director. Currently, she manages the Gynecologic Oncology clinical reserach program, which includes a broad portfolio of clinical trials, including investigator initiated studies, NCI sponsored trials (NRG, ECTCN, SWOG, etc), GOG Foundation studies, and others. Dr. Duska has 4 grown children, and lives in Charlottesville with her husband and two dogs.
Abbive (Individual(s) Involved: Self; Clinical Condition: GYN cancer): Grant/Research Support; Aduro (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; Advaxis (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; Astra Zeneca (Individual(s) Involved: Self): Advisory Board, Grant/Research Support; Cue Biopharma (Individual(s) Involved: Self; Clinical Condition: GYN cancer): Advisory Board; Eisai (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; Genentech F. Hoffmann-La Roche Ltd (Individual(s) Involved: Self): Advisory Board, Grant/Research Support; GSK (GlaxoSmithKline Group) (Individual(s) Involved: Self; Clinical Condition: GYN cancer): Grant/Research Support; Harpoon (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; Inovio (Individual(s) Involved: Self; Clinical Condition: GYN cancer): DSMC, Other Financial or Material Support; Leap Therapeutics (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; Ludwig (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; Lycera (Individual(s) Involved: Self; Clinical Condition: GYN cancer): Grant/Research Support; Merck Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: GYN clinical trials): Grant/Research Support; Morab (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; MorphoTek (Individual(s) Involved: Self; Clinical Condition: gyn cancer): Advisory Board, Grant/Research Support; Pfizer Inc (Individual(s) Involved: Self; Clinical Condition: GYN cancer): Grant/Research Support; Syndax (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support; Tesaro (Individual(s) Involved: Self; Clinical Condition: GYN Cancer): Grant/Research Support
Friday, April 29, 2022
9:00 AM – 10:00 AM
Friday, April 29, 2022
9:20 AM – 9:35 AM
Friday, April 29, 2022
9:35 AM – 10:00 AM